Abstract
The pleural mesothelium, derived from the embryonic mesoderm, is formed by a metabolically active monolayer of cells that blanket the chest wall and lungs on the parietal and visceral surfaces, respectively. The pleura and lungs are formed as a result of an intricate relationship between the mesoderm and the endoderm during development. Mesenchymal signaling pathways such as Wnt/B-catenin, Bmp4, and sonic hedgehog appear to be quintessential for lung development. Pleural Mesothelial Cells (PMCs) are known to express Wilms tumor-1 (Wt1) gene and in lineage labeling studies of the developing embryo, PMCs were found to track into the lung parenchyma and undergo mesothelial-mesenchymal transition (MMT) to form α-smooth muscle actin (α-SMA)-positive cells of the mesenchyme and vasculature. There is definite evidence that mesothelial cells can differentiate and this seems to play an important role in pleural and parenchymal pathologies. Mesothelial cells can differentiate into adipocytes, chondrocytes, and osteoblasts; and have been shown to clonally generate fibroblasts and smooth muscle cells in murine models. This supports the possibility that they may also modulate lung injury-repair by re-activation of developmental programs in the adult reflecting an altered recapitulation of development, with implications for regenerative biology of the lung. In a mouse model of lung fibrosis using lineage-tracing studies, PMCs lost their polarity and cell-cell junctional complexes, migrated into lung parenchyma, and underwent phenotypic transition into myofibroblasts in response to the pro-fibrotic mediator, transforming growth factor-β1 (TGF-β1). However, intra-pleural heme-oxygenase-1 (HO-1) induction inhibited PMC migration after intra-tracheal fibrogenic injury. Intra-pleural fluorescein isothiocyanate labeled nanoparticles decorated with a surface antibody to mesothelin, a surface marker of mesothelial cells, migrate into the lung parenchyma with PMCs supporting a potential role for pleural based therapies to modulate pleural mesothelial activation and parenchymal disease progression.
Introduction
The lung is a complex, integrated structure of airways, vasculature and interstitium, surrounded by the pleural mesothelium (Jantz and Antony, 2006). The pleural mesothelium, derived from the embryonic mesoderm, is formed by a layer of cells that blanket the chest wall and lungs on the parietal and visceral surfaces, respectively. A complex interplay of signaling pathways such as Wnt/β-catenin, Bone morphogenetic protein 4 (Bmp4), sonic hedgehog, and Fibroblast growth factor 10 (Fgf10) between the developing endoderm and mesoderm is essential for development.
Wilms tumor-1 (Wt1), a zinc finger transcription factor (Haber et al., 1990), is expressed in certain mesoderm-derived tissues including the pleura (Park et al., 1993) and is known to regulate many functional properties of the developing mesothelium (Ito et al., 2006; Jomgeow et al., 2006). It also regulates pleural mesothelial cell (PMC) plasticity. Wt1 expressing PMCs have been shown to migrate into the lung parenchyma and differentiate into subpopulations of bronchial smooth muscle cells, vascular smooth muscle cells and fibroblasts (Colvin et al., 2001; Dixit et al., 2013).
The presence of Wt1-expressing PMCs on both the pleural surface and in the lung parenchyma of patients with IPF suggests a role for crosstalk between the parenchymal lung injury and activation of the pleural mesothelium in the pathogenesis of IPF. PMCs migrate into the pulmonary parenchyma in IPF and transition into myofibroblasts suggesting the novel hypothesis that IPF is an altered, recapitulation of development, with implications for regenerative biology of the lung.
PMCs could represent a new cellular therapeutic target in a disease where we currently lack treatment modalities. Intra-pleural delivery of compounds is a lung targeted, innovative therapeutic modality that can be refined to deliver drugs, minimizing systemic toxicity.
Development
The lungs arise from the anterior foregut endoderm via a complex and highly regulated process comprising of the embryonic stage, pseudo-glandular stage, branching morphogenesis, canalicular stage, saccular stage, and the alveolarization stage. During all stages of endodermal development, the lung mesoderm interacts with the lung endoderm to generate the various lineages within the lung (Herriges and Morrisey, 2014) and plays a central role in regulating morphogenesis of the lung, including branching, lung size, and vascular development (Que et al., 2008).
Role of mesoderm during development
The lung mesoderm is an important source of paracrine signals such as Fgf10 and Wnt2 (Bellusci et al., 1997; Sekine et al., 1999; Weaver et al., 2000; Goss et al., 2009), which are essential for multiple processes during lung development, including the patterning of early endoderm progenitors, epithelial proliferation, and differentiation. The mature lung contains many mesodermal derivatives, including airway smooth muscle, vascular smooth muscle, endothelial and mesothelial cells, as well as multiple less well-understood cell types, such as pericytes, alveolar fibroblasts, and lipofibroblasts (Herriges and Morrisey, 2014). In lineage labeling studies of the developing embryo, PMCs were found to track into the lung parenchyma and undergo mesothelial-mesenchymal transition (MMT) to form α-smooth muscle actin (α-SMA)-positive cells of the mesenchyme and vasculature (Que et al., 2008).
Signaling pathways
During development, Wnt/β-catenin signaling is responsible for specifying Nkx2.1+ respiratory endoderm progenitors, which mark the specification of the respiratory system in the anterior foregut endoderm (Herriges and Morrisey, 2014). This, in turn, is dependent upon active Bmp signaling that represses the transcription factor Sox2, thereby allowing for expression of Nkx2.1. Loss of Bmp signaling through inactivation of the Bmp receptors, Bmpr1a and Bmpr1b, leads to tracheal agenesis with retention of the branching region of the lungs (Domyan et al., 2011). Moreover, signaling between the developing endoderm and mesoderm appears to be essential for branching morphogenesis and the loss of Fgf10 signaling to Fgfr2 in the developing endoderm leads to disruption of branching (Sekine et al., 1999; Ohuchi et al., 2000). Fgf10 expression is regulated by several signaling pathways such as Bmp4 and sonic hedgehog (Shh), suggesting a complex interplay of signaling molecules during development (Bellusci et al., 1997; Pepicelli et al., 1998; Weaver et al., 2000).
Wt1
The Wt1 gene encodes a 49–52 kDa protein with an N-terminal domain that is involved in protein-RNA interactions critical for its transcriptional regulatory function (Call et al., 1990).
Wt1 in prenatal development
PMCs are known to express Wt1 gene and migrate into the lung parenchyma to form smooth muscle cells of the vascular wall, as well as other cells of the lung mesenchyme during development (Que et al., 2008; Zhou et al., 2010, 2011).
Recent cell lineage labeling studies in the developing heart provide evidence that the surface epicardial mesothelium undergoes epithelial-mesenchymal transition (EMT) and migrates into the myocardium where it differentiates into various cell types, including endothelium, smooth muscle cells, and cardiomyocytes (Mikawa and Gourdie, 1996; Dettman et al., 1998; Cai et al., 2008; Zhou et al., 2010). In addition, lineage tracing and other studies show that the serosal mesothelium of the gut also contributes the majority of vascular smooth muscle cells (Wilm et al., 2005; Kawaguchi et al., 2007). A major role of Wt1 and PMCs in mesenchymal differentiation and development was demonstrated by lineage tracing studies in the embryonic mouse (Colvin et al., 2001). PMCs were shown to readily migrate into the lung parenchyma and express α-SMA. Another recent study employing Wt1CreERT2/+ mice visualized Wt1+ mesothelial cell entry into the lung by live imaging, identified their progenies in subpopulations of bronchial smooth muscle cells, vascular smooth muscle cells, and desmin+ fibroblasts by lineage tagging; and demonstrated that mesothelial cell movement into the lung requires the direct action of sonic hedgehog (shh) signaling (Dixit et al., 2013). Together, these studies demonstrate that the mesothelium lining of serosal surfaces of multiple organ systems plays a critical role during development and organogenesis, supporting the possibility that they may also modulate lung injury-repair by re-activation of developmental programs in the adult.
Wt1 in postnatal disease
Wt1 can induce a morphological transition from an epithelial phenotype to a mesenchymal phenotype (Burwell et al., 2007). It is a potent transcription factor that can function as a tumor suppressor (Zhang et al., 2003), or as an oncogene depending on the cell type (Loeb et al., 2001; Oji et al., 2002; Ueda et al., 2003). It was in fact initially discovered as a tumor suppressor gene in Wilms tumor of the kidney (Haber et al., 1990). Wt1 demonstrates tissue specific responses and is recognized to regulate TGF-β1 in the kidney. In other cell types such as hematological cells it is reported to confer oncogenic properties (Licciulli and Kissil, 2010). Wt1 is expressed in normal pleural mesothelium, and is over-expressed in malignant mesothelioma (Amin et al., 1995). However, there is limited information of the role of Wt1 in non-malignant lung diseases.
Wt1 in idiopathic pulmonary fibrosis (IPF)
Several studies support a role for Wt1 in mesothelial-to-mesenchymal transition (MMT) (Burwell et al., 2007; Bax et al., 2011a,b). Hecker et al. have evaluated the responses of PMCs to TGF-β1, their expression of MMT markers such as e-cadherin, α-SMA, vimentin; their contractile ability using a collagen gel contraction assay (Hecker et al., 2009); and also biological functional assays such as migration and proliferation (Hecker et al., 2009). Studies indicate a role for TGF-β1 in mediating MMT (Nasreen et al., 2009). For example, treatment of mouse PMCs with TGF-β1 increased expression of the myofibroblast markers α-SMA and NADPH oxidase-4 (NOX-4) (Zolak et al., 2013). Wt1-expressing PMCs are present both on the pleural surface and in the lung parenchyma of patients with IPF suggesting their role in the pathogenesis of IPF. However, the precise relationship between Wt1 and TGF-β1 remains unclear. Also, the role of Wt1 in regulating PMC plasticity needs to be analyzed.
Pluripotency of mesothelial cells
Although mesenchymal in origin, mesothelial cells exhibit characteristics such as a polygonal cell shape, expression of surface microvilli, epithelial cytokeratins, and tight junctions, which are typical of epithelial cells (Mutsaers, 2002). During development, endothelium and vascular smooth muscle cells of the vascular system, heart, liver and gut are derived from the differentiation of mesothelium via a process of epithelial-to-mesenchymal transition (EMT) (Munoz-Chapuli et al., 1999; Perez-Pomares et al., 2002, 2004). Increasing evidence suggests existence of a population of progenitor-like mesothelial cells with the capacity to differentiate into cells of different phenotypes (Herrick and Mutsaers, 2004). By targeting mesothelin and using a genetic lineage tracing approach, Rinkevich et al. (2012) demonstrated that embryonic and adult mesothelium represents a common lineage to trunk fibroblasts, smooth muscle cells, and vasculature (Rinkevich et al., 2012).
Recently, primary rat and human mesothelial cells, when maintained in osteogenic or adipogenic media, were shown to differentiate into osteoblast- and adipocyte-like cells via epithelial-to-mesenchymal transition as suggested by the changes in mRNA expression of these cells. This supports mesothelial cell differentiation as the potential source of different tissue types in malignant mesothelioma and other serosal pathologies (Lansley et al., 2011). The term mesodermoma was introduced by Donna and Betta to define neoplasms arising from undifferentiated and multipotential mesoderm (Donna and Betta, 1981).
Mesothelial cells appear to retain the ability to produce mesenchyme, including smooth muscle cells, in response to transforming growth factor-β1 (TGF-β1) and platelet derived growth factor (Wada et al., 2003; Kawaguchi et al., 2007). Moreover, mesothelial cells have been shown to adopt a myofibroblast phenotype in vitro, in response to TGF-β1 (Yang et al., 2003). Transfection of the peritoneum and pleura of rats with an adenovirus expressing TGF-β1induced mesothelial cells to undergo EMT with subsequent fibrotic changes (Margetts et al., 2005; Decologne et al., 2007).
The significance of EMT in malignant pleural mesothelioma (MPM) was demonstrated by Schramm et al. in their study of a retrospective cohort of 352 patients. Immunohistochemistry of a tissue microarray showed that the activation of periostin-triggered EMT is associated with the sarcomatoid histotype of malignant mesothelioma and has an impact on shorter survival of patients (Schramm et al., 2010). Periostin secretion by MPM cells has in turn been shown to be upregulated by CD26 (Komiya et al., 2014), the expression of which is increased in various cancers (Havre et al., 2008).
Idiopathic pulmonary fibrosis (IPF)
Sub-pleural distribution
IPF is a progressive lung disease process that appears to begin in the sub-pleural regions, and then extend centrally. This sub-pleural and basilar distribution, which is the defining feature of idiopathic pulmonary fibrosis (IPF) has not been adequately explained (King et al., 2011). However, this pattern of distribution suggests pleural involvement in the disease process.
Myofibroblasts and fibroblastic foci
The presence of myofibroblasts in fibrobastic foci in lungs of patients with IPF is well-established. The fibroblast and myofibroblast foci secrete excessive amounts of extracellular matrix, mainly collagens, resulting in scarring and destruction of the lung architecture. The profusion of fibroblastic foci is predictive of survival in IPF patients (King et al., 2001a,b). A recent study has shown that the hallmark lesion in usual interstitial pneumonia (UIP), fibroblastic foci, on three-dimensional histo-pathological reconstruction are part of a complex and highly interconnected reticulum of fibrous tissue that extends from the pleura into the lung parenchyma (Cool et al., 2006). Neither the origin of these myofibroblasts nor the molecular mechanisms involved in the formation of fibroblastic foci have been well-defined (Phan, 2008).
While a number of cellular source(s) and progenitors of tissue myofibroblasts have been proposed, none of these hypotheses provide a indisputable explanation for the histo-pathological pattern of usual interstitial pneumonia (UIP) and its peripheral localization (Raghu et al., 2011). However, evidence suggests that abnormal recapitulation of developmental pathways and epigenetic changes may play a role in the pathogenesis of IPF (King et al., 2011). IPF is a devastating disease with an inexorable course and its pathogenesis remains unclear. There are no therapies that directly impact the disease progression or mortality, and we urgently need innovative new ideas that will impact therapeutics in this disease (King et al., 2011; Raghu et al., 2011). PMCs serve as myofibroblast progenitors in animal models of fibrosis, and therapeutic targeting of these cells may be effective as an anti-fibrotic approach (Que et al., 2008).
Pleural mesothelial cells in IPF
PMCs are metabolically active cells (Antony, 2003; Mohammed et al., 2007), responsive to their microenvironment (Antony, 2003), and are recognized to demonstrate plasticity of their phenotype (Nasreen et al., 2009). The presence of calretinin and mesothelin (markers of mesothelial cells) (Mubarak et al., 2012) and Wt-1 expressing PMCs (Zolak et al., 2013) was recently demonstrated in parenchymal cells of explanted lung tissues from 16 patients with IPF supporting a role for PMC differentiation and their trafficking into the lung as contributors to the myofibroblast population in lung fibrosis. It is not known if the number or profusion of PMCs may be predictive of the severity and/or progression of IPF.
The Ashcroft score is a score for histo-pathological grading of pulmonary fibrosis (Hagiwara et al., 2000; Matsuoka et al., 2002; Simler et al., 2002; Murakami et al., 2006). There exists a correlation between the number of calretinin-positive cells and the degree of fibrotic change in the parenchyma, as measured by the Ashcroft score. Whether the number of calretinin-positive cells was measured as a raw number, or as percentage of the total nucleated cells seen in a photomicrograph, the correlation with the degree of fibrosis was highly significant (Mubarak et al., 2012). These studies suggest that PMCs may represent a novel cellular biomarker of disease activity, and more importantly, play a role in the tissue remodeling responses seen in patients with IPF.
Recent studies demonstrate that PMCs cells lose their polarity and cell-cell junctional complexes, migrate into lung parenchyma, and undergo phenotypic transition into myofibroblasts in response to the pro-fibrotic mediator, TGF-β1 (Nasreen et al., 2009; Mubarak et al., 2012). The transition of PMC to myofibroblasts is dependent on smad-2 signaling and knockdown of smad-2 gene by silencing small interfering RNA significantly suppresses the transition of PMCs to myofibroblasts and inhibits PMC haptotaxis (Nasreen et al., 2009). We have demonstrated in a murine model, that TGF-β1 induces PMC trafficking into the lung and differentiation into myofibroblasts. Moreover, carbon monoxide or the induction of heme oxygenase-1 (HO-1) inhibits the expression of myofibroblast markers, contractility, and haptotaxis in PMCs treated with TGF-β1. These findings support a potential role for pleural-based therapies to modulate pleural mesothelial activation and parenchymal fibrosis progression (Zolak et al., 2013).
Pleural mesothelial cells as a potential therapeutic target
PMCs migrate into the pulmonary parenchyma in IPF and transition into myofibroblasts. This invokes a novel, alternative hypothesis for the origin and source of the myofibroblasts in the lungs of patients with IPF, and provides a rational explanation for the spatio-temporal distribution of fibrosis in IPF. PMCs could represent a new cellular therapeutic target in a disease where we currently lack treatment options. Intra-pleural delivery of compounds is a lung targeted, innovative therapeutic modality that can be refined to deliver drugs, minimizing systemic toxicity.
Direct delivery of the small molecule inhibitors to the pleura could potentially have several advantages: (Jantz and Antony, 2006) It can potentially provide a direct, high concentration of the compound to target the pro-fibrogenic activities of PMCs; (Haber et al., 1990) Intra-pleural delivery might delay systemic absorption, protecting against systemic toxicity while increasing efficacy; (Park et al., 1993) Intra-pleural delivery may result in higher, sustained levels in the Bronchoalveolar lavage (BAL) when compared with serum levels (Mubarak et al., 2012); and (Jomgeow et al., 2006) innovative, less invasive methods of accessing the pleural space such as tunneled pleural catheters could make intra-pleural delivery a viable option in patients.
There are several methods that can be utilized for site-directed delivery of therapeutic agents. These include liposomal drug delivery, nanoparticle (NP) delivery of proteins, and gene therapy (Watanabe et al., 2010). Several of these methods have been utilized to target the pleura (Perez-Soler et al., 1997; Liu et al., 2006; Watanabe et al., 2010). We have demonstrated that PMCs migrate into the parenchyma (Zolak et al., 2013). Biodegradable fluorescein isothiocyanate (FITC) labeled PLGA (poly-lactic-co-glycolic acid) nanoparticles (which can carry therapeutic compounds conjugated to PLGA) decorated with antibody targeted to mesothelin (a PMC marker) localize to the pleural surface in control mice, but diffuse into the lung parenchyma in mice given intra-tracheal bleomycin (Figure 1). It appears that intra-pleural delivery of molecules to the lung is feasible, albeit, with the recognition that refinement of techniques for minimal lung injury will be required.
Figure 1
Intra-pleural delivery of PLGA NP. Biodegradable FITC labeled PLGA nanoparticles (which can carry therapeutic compounds conjugated to PLGA) decorated with antibody targeted to mesothelin (a PMC marker) localize to the pleural surface in control mice treated with saline (A), but diffuse into the lung parenchyma in mice given intra-tracheal bleomycin (B). The arrow point to FITC labeled PLGA nanoparticles. PLGA, Poly Lactic-co-Glycolic Acid; NP, Nanoparticles; FITC, Fluorescein isothiocyanate.
Conclusion
The pleural mesothelium is a derivative of the embryonic mesoderm. Several complex pathways of interplay between the mesoderm and endoderm lead to the development of the lungs and pleura. Lineage labeling and other studies have shown the ability of the PMCs to undergo MMT to form other mesenchymal structures and have therefore established their pluripotency during development. Moreover, recent studies have shown that the plasticity of mesothelial cells is retained postnatally and gives them the ability to migrate and differentiate into other cell types. This supports the possibility that PMCs may modulate lung injury-repair by reactivation of developmental programs in the adult, reflecting an altered recapitulation of development with implications for regenerative biology of the lung. We have shown that PMCs are present in the lung parenchyma in lungs with IPF. Also, PMC migration into lung parenchyma and phenotypic transition into myofibroblasts can be induced by the pro-fibrotic mediator, TGF-β1 and is inhibited by intra-pleural heme-oxygenase-1 (HO-1). The possible role of PMCs in disease pathogenesis and/or progression of IPF makes them an attractive cellular target for potential therapeutic interventions in a disease where we currently lack treatment modalities. Intra-pleural delivery of compounds is a lung targeted, innovative therapeutic modality that can be refined to deliver drugs, thereby minimizing systemic toxicity. Intra-pleural fluorescein isothiocyanate labeled nanoparticles decorated with a surface antibody to mesothelin, a surface marker of mesothelial cells, migrate into the lung parenchyma with PMCs supporting a potential role for pleural based therapies to modulate pleural mesothelial activation and parenchymal disease progression. However, further studies are needed to develop such therapies and effective pleural-based drug delivery systems.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- PMCs
Pleural Mesothelial Cells (PMCs)
- Wt1
Wilms tumor-1 (Wt1)
- MMT
Mesothelial-mesenchymal transition (MMT)
- α-SMA
α-smooth muscle actin
- Bmp4
Bone morphogenetic protein 4
- Shh
Sonic hedgehog
- Fgf10
Fibroblast growth factor 10
- IPF
Idiopathic Pulmonary Fibrosis
- TGF-β1
Transforming growth factor-β1
- HO-1
Heme-oxygenase-1 (HO-1)
- EMT
Epithelial-mesenchymal transition
- NOX-4
NADPH oxidase-4
- UIP
Usual interstitial pneumonia
- RNA
Ribonucleic acid
- BAL
Bronchoalveolar lavage
- NP
Nanoparticle
- FITC
Fluorescein isothiocyanate
- PLGA
Poly-lactic-co-glycolic acid.
Abbreviations
References
1
AminK. M.LitzkyL. A.SmytheW. R.MooneyA. M.MorrisJ. M.MewsD. J.et al. (1995). Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am. J. Pathol. 146, 344–356.
2
AntonyV. B. (2003). Immunological mechanisms in pleural disease. Eur Respir. J. 21, 539–544. 10.1183/09031936.03.00403902
3
BaxN. A.PijnappelsD. A.van OorschotA. A.WinterE. M.de VriesA. A.van TuynJ.et al. (2011a). Epithelial-to-mesenchymal transformation alters electrical conductivity of human epicardial cells. J. Cell. Mol. Med. 15, 2675–2683. 10.1111/j.1582-4934.2011.01266.x
4
BaxN. A.van OorschotA. A.MaasS.BraunJ.van TuynJ.de VriesA. A.et al. (2011b). In vitro epithelial-to-mesenchymal transformation in human adult epicardial cells is regulated by TGFbeta-signaling and WT1. Basic Res. Cardiol. 106, 829–847. 10.1007/s00395-011-0181-0
5
BellusciS.FurutaY.RushM. G.HendersonR.WinnierG.HoganB. L. (1997). Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development124, 53–63.
6
BurwellE. A.McCartyG. P.SimpsonL. A.ThompsonK. A.LoebD. M. (2007). Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene26, 3423–3430. 10.1038/sj.onc.1210127
7
CaiC. L.MartinJ. C.SunY.CuiL.WangL.OuyangK.et al. (2008). A myocardial lineage derives from Tbx18 epicardial cells. Nature454, 104–108. 10.1038/nature06969
8
CallK. M.GlaserT.ItoC. Y.BucklerA. J.PelletierJ.HaberD. A.et al. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell60, 509–520. 10.1016/0092-8674(90)90601-A
9
ColvinJ. S.WhiteA. C.PrattS. J.OrnitzD. M. (2001). Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development128, 2095–2106.
10
CoolC. D.GroshongS. D.RaiP. R.HensonP. M.StewartJ. S.BrownK. K. (2006). Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am. J. Respir. Crit. Care Med. 174, 654–658. 10.1164/rccm.200602-205OC
11
DecologneN.KolbM.MargettsP. J.MenetrierF.ArturY.GarridoC.et al. (2007). TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J. Immunol. 179, 6043–6051. 10.4049/jimmunol.179.9.6043
12
DettmanR. W.DenetclawW.Jr.OrdahlC. P.BristowJ. (1998). Common epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and intermyocardial fibroblasts in the avian heart. Dev. Biol. 193, 169–181. 10.1006/dbio.1997.8801
13
DixitR.AiX.FineA. (2013). Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry. Development140, 4398–4406. 10.1242/dev.098079
14
DomyanE. T.FerrettiE.ThrockmortonK.MishinaY.NicolisS. K.SunX. (2011). Signaling through BMP receptors promotes respiratory identity in the foregut via repression of Sox2. Development138, 971–981. 10.1242/dev.053694
15
DonnaA.BettaP. G. (1981). Mesodermomas: a new embryological approach to primary tumours of coelomic surfaces. Histopathology. 5, 31–44. 10.1111/j.1365-2559.1981.tb01764.x
16
GossA. M.TianY.TsukiyamaT.CohenE. D.ZhouD.LuM. M.et al. (2009). Wnt2/2b and beta-catenin signaling are necessary and sufficient to specify lung progenitors in the foregut. Dev. Cell17, 290–298. 10.1016/j.devcel.2009.06.005
17
HaberD. A.BucklerA. J.GlaserT.CallK. M.PelletierJ.SohnR. L.et al. (1990). An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell61, 1257–1269. 10.1016/0092-8674(90)90690-G
18
HagiwaraS. I.IshiiY.KitamuraS. (2000). Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am. J. Respir. Crit. Care Med. 162, 225–231. 10.1164/ajrccm.162.1.9903129
19
HavreP. A.AbeM.UrasakiY.OhnumaK.MorimotoC.DangN. H. (2008). The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 13, 1634–1645. 10.2741/2787
20
HeckerL.VittalR.JonesT.JagirdarR.LuckhardtT. R.HorowitzJ. C.et al. (2009). NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15, 1077–1081. 10.1038/nm.2005
21
HerrickS. E.MutsaersS. E. (2004). Mesothelial progenitor cells and their potential in tissue engineering. Int. J. Biochem. Cell Biol. 36, 621–642. 10.1016/j.biocel.2003.11.002
22
HerrigesM.MorriseyE. E. (2014). Lung development: orchestrating the generation and regeneration of a complex organ. Development141, 502–513. 10.1242/dev.098186
23
ItoK.OjiY.TatsumiN.ShimizuS.KanaiY.NakazawaT.et al. (2006). Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene25, 4217–4229. 10.1038/sj.onc.1209455
24
JantzM. A.AntonyV. B. (2006). Pleural fibrosis. Clin. Chest Med. 27, 181–191. 10.1016/j.ccm.2005.12.003
25
JomgeowT.OjiY.TsujiN.IkedaY.ItoK.TsudaA.et al. (2006). Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci. 97, 259–270. 10.1111/j.1349-7006.2006.00169.x
26
KawaguchiM.BaderD. M.WilmB. (2007). Serosal mesothelium retains vasculogenic potential. Dev. Dyn. 236, 2973–2979. 10.1002/dvdy.21334
27
KingT. E.Jr.PardoA.SelmanM. (2011). Idiopathic pulmonary fibrosis. Lancet378, 1949–1961. 10.1016/S0140-6736(11)60052-4
28
KingT. E.Jr.SchwarzM. I.BrownK.ToozeJ. A.ColbyT. V.WaldronJ. A.Jr.et al. (2001a). Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med. 164, 1025–1032. 10.1164/ajrccm.164.6.2001056
29
KingT. E.Jr.ToozeJ. A.SchwarzM. I.BrownK. R.CherniackR. M. (2001b). Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 164, 1171–1181. 10.1164/ajrccm.164.7.2003140
30
KomiyaE.OhnumaK.YamazakiH.HatanoR.IwataS.OkamotoT.et al. (2014). CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells. Biochem. Biophys. Res. Commun. 447, 609–615. 10.1016/j.bbrc.2014.04.037
31
LansleyS. M.SearlesR. G.HoiA.ThomasC.MonetaH.HerrickS. E.et al. (2011). Mesothelial cell differentiation into osteoblast- and adipocyte-like cells. J. Cell. Mol. Med. 15, 2095–2105. 10.1111/j.1582-4934.2010.01212.x
32
LicciulliS.KissilJ. L. (2010). WT1: a weak spot in KRAS-induced transformation. J. Clin. Invest. 120, 3804–3807. 10.1172/JCI44901
33
LiuJ.WongH. L.MoselhyJ.BowenB.WuX. Y.JohnstonM. R. (2006). Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer51, 377–386. 10.1016/j.lungcan.2005.11.006
34
LoebD. M.EvronE.PatelC. B.SharmaP. M.NiranjanB.BuluwelaL.et al. (2001). Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61, 921–925.
35
MargettsP. J.BonniaudP.LiuL.HoffC. M.HolmesC. J.West-MaysJ. A.et al. (2005). Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 16, 425–436. 10.1681/ASN.2004060436
36
MatsuokaH.AraiT.MoriM.GoyaS.KidaH.MorishitaH.et al. (2002). A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 283, L103–L112.
37
MikawaT.GourdieR. G. (1996). Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev. Biol. 174, 221–232. 10.1006/dbio.1996.0068
38
MohammedK. A.NasreenN.AntonyV. B. (2007). Bacterial induction of early response genes and activation of proapoptotic factors in pleural mesothelial cells. Lung185, 355–365. 10.1007/s00408-007-9046-6
39
MubarakK. K.Montes-WorboysA.RegevD.NasreenN.MohammedK. A.FaruqiI.et al. (2012). Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur. Respir. J. 39, 133–140. 10.1183/09031936.00141010
40
Munoz-ChapuliR.Perez-PomaresJ. M.MaciasD.Garcia-GarridoL.CarmonaR.GonzalezM. (1999). Differentiation of hemangioblasts from embryonic mesothelial cells? A model on the origin of the vertebrate cardiovascular system. Differentiation64, 133–141. 10.1007/s002580050268
41
MurakamiS.NagayaN.ItohT.KataokaM.IwaseT.HorioT.et al. (2006). Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L59–L65. 10.1152/ajplung.00042.2005
42
MutsaersS. E. (2002). Mesothelial cells: their structure, function and role in serosal repair. Respirology7, 171–191. 10.1046/j.1440-1843.2002.00404.x
43
NasreenN.MohammedK. A.MubarakK. K.BazM. A.AkindipeO. A.Fernandez-BussyS.et al. (2009). Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L115–L124. 10.1152/ajplung.90587.2008
44
OhuchiH.HoriY.YamasakiM.HaradaH.SekineK.KatoS.et al. (2000). FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem. Biophys. Res. Commun. 277, 643–649. 10.1006/bbrc.2000.3721
45
OjiY.MiyoshiS.MaedaH.HayashiS.TamakiH.NakatsukaS.et al. (2002). Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int. J. Cancer100, 297–303. 10.1002/ijc.10476
46
ParkS.SchallingM.BernardA.MaheswaranS.ShipleyG. C.RobertsD.et al. (1993). The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat. Genet. 4, 415–420. 10.1038/ng0893-415
47
PepicelliC. V.LewisP. M.McMahonA. P. (1998). Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr. biol. 8, 1083–1086. 10.1016/S0960-9822(98)70446-4
48
Perez-PomaresJ. M.CarmonaR.Gonzalez-IriarteM.AtenciaG.WesselsA.Munoz-ChapuliR. (2002). Origin of coronary endothelial cells from epicardial mesothelium in avian embryos. Int. J. Dev. Biol. 46, 1005–1013.
49
Perez-PomaresJ. M.CarmonaR.Gonzalez-IriarteM.MaciasD.GuadixJ. A.Munoz-ChapuliR. (2004). Contribution of mesothelium-derived cells to liver sinusoids in avian embryos. Dev. Dyn229, 465–474. 10.1002/dvdy.10455
50
Perez-SolerR.ShinD. M.SiddikZ. H.MurphyW. K.HuberM.LeeS. J.et al. (1997). Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin. Cancer Res. 3, 373–379.
51
PhanS. H. (2008). Biology of fibroblasts and myofibroblasts. Proc. Am. Thorac. Soc. 5, 334–337. 10.1513/pats.200708-146DR
52
QueJ.WilmB.HasegawaH.WangF.BaderD.HoganB. L. (2008). Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. Proc. Natl. Acad. Sci. U.S.A. 105, 16626–16630. 10.1073/pnas.0808649105
53
RaghuG.CollardH. R.EganJ. J.MartinezF. J.BehrJ.BrownK. K.et al. (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788–824. 10.1164/rccm.2009-040GL
54
RinkevichY.MoriT.SahooD.XuP. X.BerminghamJ. R.Jr.WeissmanI. L. (2012). Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat. Cell Biol. 14, 1251–1260. 10.1038/ncb2610
55
SchrammA.OpitzI.ThiesS.SeifertB.MochH.WederW.et al. (2010). Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 37, 566–572. 10.1016/j.ejcts.2009.08.027
56
SekineK.OhuchiH.FujiwaraM.YamasakiM.YoshizawaT.SatoT.et al. (1999). Fgf10 is essential for limb and lung formation. Nat. Genet. 21, 138–141. 10.1038/5096
57
SimlerN. R.HowellD. C.MarshallR. P.GoldsackN. R.HasletonP. S.LaurentG. J.et al. (2002). The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir. J. 19, 1124–1127. 10.1183/09031936.02.00281602
58
UedaT.OjiY.NakaN.NakanoY.TakahashiE.KogaS.et al. (2003). Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci. 94, 271–276. 10.1111/j.1349-7006.2003.tb01432.x
59
WadaA. M.SmithT. K.OslerM. E.ReeseD. E.BaderD. M. (2003). Epicardial/Mesothelial cell line retains vasculogenic potential of embryonic epicardium. Circ. Res. 92, 525–531. 10.1161/01.RES.0000060484.11032.0B
60
WatanabeM.BoyerJ. L.CrystalR. G. (2010). AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther. 17, 1042–1051. 10.1038/gt.2010.87
61
WeaverM.DunnN. R.HoganB. L. (2000). Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis. Development127, 2695–2704.
62
WilmB.IpenbergA.HastieN. D.BurchJ. B.BaderD. M. (2005). The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. Development132, 5317–5328. 10.1242/dev.02141
63
YangA. H.ChenJ. Y.LinJ. K. (2003). Myofibroblastic conversion of mesothelial cells. Kidney Int. 63, 1530–1539. 10.1046/j.1523-1755.2003.00861.x
64
ZhangT. F.YuS. Q.GuanL. S.WangZ. Y. (2003). Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin. Anticancer Res. 23, 3575–3584.
65
ZhouB.HonorL. B.HeH.MaQ.OhJ. H.ButterfieldC.et al. (2011). Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J. Clin. Invest. 121, 1894–1904. 10.1172/JCI45529
66
ZhouB.von GiseA.MaQ.HuY. W.PuW. T. (2010). Genetic fate mapping demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian heart. Dev. Biol. 338, 251–261. 10.1016/j.ydbio.2009.12.007
67
ZolakJ. S.JagirdarR.SuroliaR.KarkiS.OlivaO.HockT.et al. (2013). Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury. Am. J. Pathol. 182, 1239–1247. 10.1016/j.ajpath.2012.12.030
Summary
Keywords
pleural mesothelium, pleural mesothelial cells, idiopathic pulmonary fibrosis (IPF), Wilms tumor-1 (WT1), epithelial-mesenchymal transition (EMT)
Citation
Batra H and Antony VB (2014) The pleural mesothelium in development and disease. Front. Physiol. 5:284. doi: 10.3389/fphys.2014.00284
Received
27 May 2014
Accepted
10 July 2014
Published
01 August 2014
Volume
5 - 2014
Edited by
Sotirios G. Zarogiannis, University of Thessaly, Greece
Reviewed by
Vassilios Liakopoulos, Aristotle University of Thessaloniki, Greece; K. Onuma, Juntendo University, Japan
Copyright
© 2014 Batra and Antony.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hitesh Batra, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 1900 University Blvd., THT 422, Birmingham, AL 35294-0006, USA e-mail: hiteshbatra921@gmail.com
This article was submitted to Membrane Physiology and Membrane Biophysics, a section of the journal Frontiers in Physiology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.